The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program
Open accessAbstract
BACKGROUND: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. METHODS: Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3 mg/kg every 2 weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The association between overall survival (OS) and irAEs was assessed, and associations between variables were evaluated with a logistic regression model. RESULTS: A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% CI 3.7-6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3-4 drAEs were reported in 124 (32%) and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%) of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than those without drAEs (median OS 22.5 versus 16.4 months, p = 0.01). Pts with irAEs versus without irAEs had a more significant survival benefit (median OS not reached versus 16.8 months, p = 0.002), confirmed at the landmark analysis at 6 weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p = 0.003) and multivariable (HR 0.57, p = 0.02) analysis. CONCLUSIONS: The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts treated with nivolumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Patients who experienced IRAEs had prolonged OS compared to those who did not experience them (NR vs 16.8 months, p = .002).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“In the included patients, 20% experienced any IRAEs with the most common sites being dermatologic (8%), gastrointestinal (5%) and endocrine (4%).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [40]
In the citing paper
“In terms of 1-year OS, 1-year OS was 75.4 and 59.8% in patients who did and did not experience IRAEs, respectively.”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Self-citationBrahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863
Cited by
Sorted by citations
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145
Advances in cancer immunotherapy 2019 – latest trends
Krüger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schlößer, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 564
Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020) · BMC Medicine · doi:10.1186/s12916-020-01549-2 · Cited by 368
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 312
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 247
Ghisoni, E., Wicky, A. M., Bouchaab, H., Imbimbo, M., Delyon, J., Moura, B. G., Gerard, C. L., Latifyan, S., Özdemir, B. C., Caikovski, M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.03.010 · Cited by 213
Dall’Olio, F. G., Rizzo, A., Mollica, V., Massucci, M., Maggio, I., & Massari, F. (2020) · Immunotherapy · doi:10.2217/imt-2020-0179 · Cited by 140
Cortellini, A., Bersanelli, M., Santini, D., Buti, S., Tiseo, M., Cannita, K., Perrone, F., Giusti, R., Tursi, M. D., Zoratto, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.031 · Cited by 127
Self-citationHarnessing big data to characterize immune-related adverse events
Jing, Y., Yang, J., Johnson, D. B., Moslehi, J. J., & Han, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00597-8 · Cited by 125
Fan, Y., Xie, W., Huang, H., Wang, Y., Li, G., Geng, Y., Hao, Y., & Zhang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633032 · Cited by 125
Jing, Y., Chen, X., Li, K., Liu, Y., Zhang, Z., Chen, Y., Liu, Y., Wang, Y., Lin, S. H., Diao, L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003779 · Cited by 120
van Holstein, Y., Kapiteijn, E., Bastiaannet, E., van den Bos, F., Portielje, J. E. A., & de Glas, N. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00697-2 · Cited by 114
Gut microbiota-mediated immunomodulation in tumor
Liu, X., Chen, Y., Zhang, S., & Dong, L. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01983-x · Cited by 112
Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy
Jing, Y., Zhang, Y., Wang, J., Li, K., Chen, X., Heng, J., Gao, Q., Ye, Y., Zhang, Z., Liu, Y., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab035 · Cited by 103
Cheung, Y.-M. M., Wang, W., McGregor, B. A., & Hamnvik, O. R. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03128-7 · Cited by 101
Basak, E. A., van der Meer, J. W. M., Hurkmans, D. P., Schreurs, M. W. J., Hoop, E. O., van der Veldt, A. A. M., Bins, S., Joosse, A., Koolen, S. L. W., Debets, R., et al. (2020) · Thyroid · doi:10.1089/thy.2019.0726 · Cited by 92
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine
Herati, R. S., Knorr, D. A., Vella, L. A., Silva, L. V., Chilukuri, L., Apostolidis, S. A., Huang, A. C. C., Muselman, A., Manne, S., Kuthuru, O., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01274-3 · Cited by 82
Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors
Zhong, L., Wu, Q., Chen, F., Liu, J., & Xie, X. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02803-5 · Cited by 87
Foster, C. C., Couey, M., Kochanny, S. E., Khattri, A., Acharya, R. K., Tan, Y. C., Brisson, R. J., Leidner, R. S., & Seiwert, T. Y. (2021) · Cancer · doi:10.1002/cncr.33780 · Cited by 83
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Raimondi, A., Sepe, P., Zattarin, E., Mennitto, A., Stellato, M., Claps, M., Guadalupi, V., Verzoni, E., de Braud, F., & Procopio, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01644 · Cited by 76
Self-citationPaderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., & Antonuzzo, L. (2021) · Cancers · doi:10.3390/cancers13040860 · Cited by 62
Cortellini, A., Buti, S., Agostinelli, V., & Bersanelli, M. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.10.003 · Cited by 62
Self-citationHanna, G. J., Ruiz, E. S., LeBoeuf, N. R., Thakuria, M., Schmults, C. D., DeCaprio, J. A., & Silk, A. W. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01044-8 · Cited by 62
Mangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 62
Zhao, Z., Wang, X., Qu, J., Zuo, W., Tang, Y., Zhu, H., & Chen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708195 · Cited by 49
Park, R., Lopes, L., & Saeed, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02397-5 · Cited by 50
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Attalla, K., Weng, S., Voss, M. H., & Hakimi, A. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.002 · Cited by 51
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 48
Kato, T., Kiyotani, K., Tomiyama, E., Koh, Y., Matsushita, M., Hayashi, Y., Nakano, K., Ishizuya, Y., Wang, C., Hatano, K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1862948 · Cited by 47
Bastacky, M. L., Wang, H., Fortman, D. D., Rahman, Z., Mascara, G. P., Brenner, T., Najjar, Y. G., Luke, J. J., Kirkwood, J. M., Zarour, H. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749064 · Cited by 49
Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J., Guimbaud, R., Meyer, N., Mazières, J., & Alric, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1682383 · Cited by 47
Fukushima, T., Morimoto, M., Kobayashi, S., Ueno, M., Uojima, H., Hidaka, H., Kusano, C., Chuma, M., Numata, K., Tsuruya, K., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad090 · Cited by 46
The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors
Fukushima, T., Kobayashi, S., & Ueno, M. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae067 · Cited by 48
Management of Immune Checkpoint Inhibitor Toxicities
Durrechou, Q., Domblides, C., Sionneau, B., Lefort, F., Quivy, A., Ravaud, A., Gross‐Goupil, M., & Daste, A. (2020) · Cancer Management and Research · doi:10.2147/cmar.s218756 · Cited by 37
von Itzstein, M. S., Gonugunta, A. S., Wang, Y., Sheffield, T. Y., Lü, R., Ali, S., Fattah, F. J., Xie, D., Cai, J. X., Xie, Y., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03151-2 · Cited by 36
Fiala, O., Šorejs, O., Šustr, J., Kučera, R., Topolčan, O., & Fínek, J. (2020) · Anticancer Research · doi:10.21873/anticanres.14063 · Cited by 34
Shalata, W., Weissmann, S., Gabay, S. I., Sheva, K., Saleh, O. A., Jama, A. A., Yakobson, A., & Rouvinov, K. (2022) · Cancers · doi:10.3390/cancers14215451 · Cited by 35
Ikeda, T., Ishihara, H., Nemoto, Y., Tachibana, H., Fukuda, H., Yoshida, K., Takagi, T., Iizuka, J., Hashimoto, Y., Ishida, H., et al. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.012 · Cited by 32
PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
Zhang, K., Kong, X., Li, Y., Wang, Z., Zhang, L., & Xuan, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.854967 · Cited by 34
Zhao, J., Li, D., Xie, S., Deng, X., Wen, X., Li, J., Wu, Z., Yang, X., Li, M., Tang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1083840 · Cited by 33
Diabetes mellitus induced by immune checkpoint inhibitors
Zheng, Z., Liu, Y., Yang, J., Tan, C., Zhou, L., Wang, X., Li, X., Zhang, S., Chen, Y., & Liu, X. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3366 · Cited by 32
Bae, J.-H., Baek, Y., Lee, J. E., Song, I., Lee, J.-H., & Shin, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602365 · Cited by 36
Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience
Zhao, J. J., Kumarakulasinghe, N., Muthu, V., Lee, M., Walsh, R., Low, J., Choo, J., Tan, L., Chong, W.-Q., Ang, Y., et al. (2021) · Oncology · doi:10.1159/000512000 · Cited by 25
Pozzessere, C., Mazini, B., Omoumi, P., Jreige, M., Noirez, L., Digklia, A., Fasquelle, F., Sempoux, C. L., & Dromain, C. (2024) · Cancers · doi:10.3390/cancers16142585 · Cited by 32
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy
Chiloiro, S., Bianchi, A., Giampietro, A., Milardi, D., Marinis, L. D., & Pontecorvi, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.10.009 · Cited by 32
Zhang, Y., Chen, J., Liu, H., Dai, J., Zhao, J., Zhu, S., Zhang, X., Liang, J., Hu, X., Zhao, J., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102787 · Cited by 28
Portenkirchner, C., Kienle, P., & Horisberger, K. (2021) · Pharmaceuticals · doi:10.3390/ph14040367 · Cited by 29
SEOM clinical guideline for treatment of kidney cancer (2019)
Lázaro-Quintela, M., Valderrama, B. P., Suárez, C., de Velasco, G., Beato, C., Chirivella, I., del Alba, A. G., Laínez, N., Méndez-Vidal, M. J., & Arranz, J. Á. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02285-7 · Cited by 28
Kijima, T., Fukushima, H., Kusuhara, S., Tanaka, H., Yoshida, S., Yokoyama, M., Ishioka, J., Matsuoka, Y., Numao, N., Sakai, Y., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.07.003 · Cited by 26
Kubo, T., Hirohashi, Y., Tsukahara, T., Kanaseki, T., Murata, K., Morita, R., & Torigoe, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1976942 · Cited by 25
Washino, S., Shirotake, S., Takeshita, H., Inoue, M., Miura, Y., Hyodo, Y., Kagawa, M., Izumi, K., Oyama, M., Kawakami, S., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02406-x · Cited by 27
Hinata, N., Yonese, J., Masui, S., Nakai, Y., Shirotake, S., Tatsugami, K., Inamoto, T., Nozawa, M., Ueda, K., Etsunaga, T., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01692-z · Cited by 24
Schulz, G. B., Rodler, S., Szabados, B. E., Graser, A., Büchner, A., Stief, C. G., & Casuscelli, J. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.06.012 · Cited by 25
Guida, A., Sabbatini, R., Gibellini, L., Biasi, S. D., Cossarizza, A., & Porta, C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102157 · Cited by 23
Self-citationSerna-Higuita, L. M., Amaral, T. M. S., Forschner, A., Leiter, U., Flatz, L., Seeber, O., Thomas, I., Garbe, C., Eigentler, T., & Martus, P. (2021) · Cancers · doi:10.3390/cancers13236141 · Cited by 23
Paschou, S. Α., Liontos, M., Eleftherakis-Papaiakovou, E., Stefanaki, K., Markellos, C., Koutsoukos, K., Zagouri, F., Ψαλτοπούλου, Θ., & Dimopoulos, M. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847917 · Cited by 23
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 30
The role of immunotherapy in advanced renal cell carcinoma
Mondlane, E. R., Abreu‐Mendes, P., Martins, D. F., Cruz, R., & Mendes, F. (2021) · International braz j urol · doi:10.1590/s1677-5538.ibju.2020.0681 · Cited by 26
Vitale, M. G., Pipitone, S., Venturelli, M., Baldessari, C., Porta, C., Iannuzzi, F., Basso, U., Scagliarini, S., Zucali, P. A., Galli, L., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.05.010 · Cited by 22
Self-citationde la Bruyère, C. L., Souquet, P.-J., Dalle, S., Corbaux, P., Boespflug, A. M., Duruisseaux, M., Kiakouama-Maleka, L., Reverdy, T., Maugeais, M., Şahin, G., et al. (2021) · Cancers · doi:10.3390/cancers13102365 · Cited by 21
Riveiro‐Barciela, M., Carballal, S., Díaz‐González, Á., Mañosa, M., Gallego-Plazas, J., Cubiella, J., Jiménez‐Fonseca, P., Varela, M., Menchen, L. A., Sangro, B., et al. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2023.10.009 · Cited by 22
Mehra, T., Dongre, K., Boesing, M., Frei, P., Suenderhauf, C., Zippelius, A., Leuppi, J. D., WICKI, A. N., & Leuppi-Taegtmeyer, A. B. (2023) · Cancer Medicine · doi:10.1002/cam4.5919 · Cited by 18
Hara, Y., Baba, Y., Toihata, T., Harada, K., Ogawa, K., Iwatsuki, M., Iwagami, S., Miyamoto, Y., Yoshida, N., & Baba, H. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-281 · Cited by 18
Zhang, Y.-C., Zhu, T.-C., Nie, R., Lu, L., Xiang, Z., Xie, D., Luo, R., & Cai, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030736 · Cited by 18
Immunotherapy in Renal Cell Carcinoma from Poverty to the Spoiled of Choice
Massari, F., Nunno, V. D., Mollica, V., Montironi, R., Liang Cheng, C., Cimadamore, A., Blanca, A., & Antonio Lopez-beltran, B. (2019) · Immunotherapy · doi:10.2217/imt-2019-0115 · Cited by 18
Deng, R., Zhang, H., Li, Y., & Shi, Y. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000442 · Cited by 17
Economopoulou, P., Kotsantis, I., Papaxoinis, G., Gavrielatou, N., Anastasiou, Μ., Pantazopoulos, A., Kavourakis, G., Gkolfinopoulos, S., Panayiotides, I. G., Delides, A., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105013 · Cited by 17
Idelalisib immune-related toxicity is associated with improved treatment response
Wagner‐Johnston, N. D., Sharman, J. P., Furman, R. R., Salles, G., Brown, J. R., Robak, T., Gu, L., Xing, G., Chan, R. J., Rajakumaraswamy, N., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1948038 · Cited by 18
Basso, U., Paolieri, F., Rizzo, M., Giorgi, U. D., Sergio Bracarda, A., Antonuzzo, L., Atzori, F., Cartenì, G., Procopio, G., Fratino, L., et al. (2022) · Cancers · doi:10.3390/cancers14092293 · Cited by 15
Self-citationAri, S. L., Serzan, M. T., Wu, T., Ip, A., Pascual, L., Sinclaire, B., Adams, S., Marafelias, M., Ayyagari, L., Gill, S. K., et al. (2023) · Cancer · doi:10.1002/cncr.34742 · Cited by 17
Ni, J., Si, X., Wang, H., Zhang, X., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168879 · Cited by 15
Hino, C., Nishino, K., Pham, B., Jeon, W. J., Nguyen, M., & Cao, H. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993622 · Cited by 14
Kato, T., Nagahara, A., Kawamura, N., Nakata, W., Soda, T., Matsuzaki, K., Hatano, K., Kawashima, A., Ujike, T., Imamura, R., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01872-5 · Cited by 13
Silberg, M., Krabbe, L., Bögemann, M., Schrader, A. J., Tully, K. H., & Schlack, K. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102164 · Cited by 12
Rambhia, A., Patel, R. D., Okhawere, K. E., Korn, T. G., & Badani, K. K. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.06.013 · Cited by 11
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma
Sepe, P., Mennitto, A., Corti, F., & Procopio, G. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s240889 · Cited by 11
Self-citationAoki, T., Kagawa, N., Sugiyama, K., Wakabayashi, T., Arakawa, Y., Yamaguchi, S., Tanaka, S., Ishikawa, E., Muragaki, Y., Nagane, M., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02028-1 · Cited by 11
Booka, E., Kikuchi, H., Haneda, R., Soneda, W., Kawata, S., Murakami, T., Matsumoto, T., Hiramatsu, Y., & Takeuchi, H. (2021) · In Vivo · doi:10.21873/invivo.12506 · Cited by 11
Fang, J., Zhong, S., Wang, T., He, K., Mu, A., Ong, M., Lin, Y., Zhu, Z., Wang, N., Wu, J., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-336719 · Cited by 10
Ishihara, H., Yuki, N., Ishiyama, R., Ikeda, T., Kobari, Y., Fukuda, H., Yoshida, K., Shimmura, H., Hashimoto, Y., Iizuka, J., et al. (2024) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyae001 · Cited by 11
Olsson-Brown, A. C., Jain, A., Frazer, R. D., Farrugia, D., Carser, J., Houghton, J. B., Lewis, R. D., D'Mello, S., & Emanuel, G. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00349-z · Cited by 13
Resch, I., Bruchbacher, A., Franke, J., Fajković, H., Mesut Remzi, A., Shariat, S. F., & Schmidinger, M. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100122 · Cited by 10
Martini, D. J., Evans, S. T., Liu, Y., Shabto, J. M., Uner, O. E., Olsen, T. A., Brown, J. T., Russler, G. A., Yantorni, L. B., Caulfield, S. E., et al. (2021) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2021.11.004 · Cited by 11
Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches
Flavell, R. R., Evans, M. J., Villanueva-Meyer, J. E., & Yom, S. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.06.025 · Cited by 10
Adda, L., Batteux, B., Saidak, Z., Poulet, C., Arnault, J., Chauffert, B., & Séjourné, A. (2021) · Joint Bone Spine · doi:10.1016/j.jbspin.2021.105168 · Cited by 11
Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study
Storm, B. N., Kalkhoran, H. A., Wilms, E. B., Brocken, P., Codrington, H., Houtsma, D., Portielje, J. E. A., de Glas, N. A., van der Ziel, D., van den Bos, F., et al. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.05.013 · Cited by 11
Seydel, F., Delécluse, S., Zeier, M. G., Holland-Letz, T., Haag, G. M., Berger, A. K., Grün, B. C., Bougatf, N., Hohenfellner, M., Duensing, S. M., et al. (2021) · Cancers · doi:10.3390/cancers13071623 · Cited by 10
Immune checkpoint inhibitors: From friend to foe
Rajak, P. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102033 · Cited by 9
Hall, J., Zanotti, G., Kim, R., Krulewicz, S., Leith, A., Bailey, A., Liu, F. X., & Kearney, M. (2021) · Future Oncology · doi:10.2217/fon-2020-1266 · Cited by 9
Li, Z., Xia, Y., Xia, M., Liu, C. X., Wang, T., Liu, Y., & Ren, Y. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-254 · Cited by 9
Abdihamid, O., Athman, A., & Rugambwa, T. K. (2021) · ecancermedicalscience · doi:10.3332/ecancer.2021.1314 · Cited by 9
Waddell, T. K., Fife, K. M., Griffiths, R., Sharma, A., Dhokia, P., Groves, L., Hurst, M. A., Tsang, C., Sugrue, D., McKenna, S., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09694-y · Cited by 8
Zhao, Y., Cong, D., Zhang, W., Jia, Y., & Bai, Y. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-75 · Cited by 8
Nukaya, T., Takahara, K., Yoshizawa, A., Saruta, M., Yano, Y., Ohno, T., Uchimoto, T., Fukuokaya, W., Adachi, T., Yamazaki, S., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.09.007 · Cited by 8
Raimondi, A., Sepe, P., Claps, M., Verzoni, E., & Procopio, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1651288 · Cited by 8
Self-citationSoto, C. M. V., Palomares, M. V. V., Fernández-Cueto, A. G.-A., Villanueva, S. B., Callejo, V. M., Sufrategui, M. O., Muñoz, P., & Domínguez, M. V. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-003038 · Cited by 7
Noel, J., Jouinot, A., Alexandre, J., Ulmann, G., Bretagne, M., Ajgal, Z. C., Percin, S. D., Villeminey, C., Revel, M., Peyromaure, M., et al. (2022) · Cancers · doi:10.3390/cancers14133214 · Cited by 7
Maruzzo, M., Pierantoni, F., Bortolami, A., Palleschi, D., Zivi, A., Nicodemo, M., Sartori, D., Vivo, R. D., Zustovich, F., Bimbatti, D., et al. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00892-z · Cited by 7
Metadata
- Authors
- on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group, Verzoni, E., Cartenì, G., Cortesi, E., Giannarelli, D., De Giglio, A., Sabbatini, R., Buti, S., Rossetti, S., Cognetti, F., Rastelli, F., Sobrero, A., Turci, D., Sternberg, C. N., Porta, C., Cappuzzo, F., Tortora, G., Tassinari, D., Panni, S., Pazzola, A., Surico, G., Raimondi, A., De Giorgi, U., & Procopio, G.
- Affiliations
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Ospedale Antonio Cardarelli (IT)
- Policlinico Umberto I (IT)
- Azienda Ospedaliera S.Maria (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Ospedale di Parma (IT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Ospedale Policlinico San Martino (IT)
- Ospedale "Santa Maria delle Croci" di Ravenna (IT)
- University of Pavia (IT)
- Azienda Ospedaliera Universitaria Integrata Verona (IT)
- Ospedale Infermi di Rimini (IT)
- Istituti Ospitalieri di Cremona (IT)
- Ospedale Vito Fazzi (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Corresponding author
- on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group
- ORCID
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2019-04-03
- Volume
- 7
- Issue
- 1
- Pages
- 99-99
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC6448290
- OpenAlex
- W2942674623
- Cited by
- 140
- References
- 30
- Citations by year
- 2026: 2 · 2025: 14 · 2024: 12 · 2023: 14 · 2022: 29 · 2021: 38 · 2020: 23 · 2019: 8
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Funders
- Bristol-Myers Squibb (not applicable)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, metastatic renal cell carcinoma, immune-related adverse events, expanded access program, overall survival, drug-related adverse events, immune checkpoint inhibitors, treatment discontinuation, progression-free survival, objective response rate, cutaneous adverse events, endocrine adverse events, hepatic adverse events, pulmonary adverse events, previously treated patients, real-world efficacy and safety
- MeSH terms
- Antineoplastic Agents, Immunological, Nivolumab, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Italy, Kidney Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Severity of Illness Index, Survival Rate, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
